Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.